Cargando…
OR26-03 Treatment With Linsitinib, An IGF-1 Receptor Inhibitor, Prevents Disease Development And Progression In An Experimental Model Of Thyroid Eye Disease
Disclosure: A. Gulbins: Grant Recipient; Self; Sling therapeutics, Inc. M. Horstmann: Grant Recipient; Self; Sling therapeutics, Inc. A. Daser: None. U. Flögel: None. M. Oeverhaus: Grant Recipient; Self; Sling therapeutics, Inc. B.E. Nikolaos: None. J.P. Banga: None. G. Krause: None. G.D. Hammer: Re...
Autores principales: | Gulbins, Anne, Horstmann, Mareike, Daser, Anke, Flögel, Ulrich, Oeverhaus, Michael, Nikolaos, Bechrakis E, Paul Banga, J, Krause, Gerd, Hammer, Gary D, Spencer, Andrew G, Zeidan, Ryan, Eckstein, Anja, Philipp, Svenja, Görtz, Gina-Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10555290/ http://dx.doi.org/10.1210/jendso/bvad114.2052 |
Ejemplares similares
-
Linsitinib, an IGF-1R inhibitor, attenuates disease development and progression in a model of thyroid eye disease
por: Gulbins, Anne, et al.
Publicado: (2023) -
Potential involvement of the bone marrow in experimental Graves’ disease and thyroid eye disease
por: Gulbins, Anne, et al.
Publicado: (2023) -
Graves’ orbitopathy occurs sex-independently in an autoimmune hyperthyroid mouse model
por: Schlüter, Anke, et al.
Publicado: (2018) -
Novel Insights into Pathophysiology of Orbital Inflammatory Diseases and Progression to Orbital Lymphoma by Pathway Enrichment Analysis
por: Al-Ghazzawi, Karim, et al.
Publicado: (2022) -
Influence of biological sex, age and smoking on Graves’ orbitopathy – a ten-year tertiary referral center analysis
por: Oeverhaus, Michael, et al.
Publicado: (2023)